- Home
- PSNL vs TLSA Comparison
PSNL vs TLSA Comparison
Compare PSNL & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- TLSA
- Stock Information
- Founded
- PSNL 2011
- TLSA 2013
- Country
- PSNL United States
- TLSA United Kingdom
- Employees
- PSNL N/A
- TLSA N/A
- Industry
- PSNL Medical Specialities
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- PSNL Health Care
- TLSA Health Care
- Exchange
- PSNL Nasdaq
- TLSA Nasdaq
- Market Cap
- PSNL 321.1M
- TLSA 87.8M
- IPO Year
- PSNL 2019
- TLSA 2000
- Fundamental
- Price
- PSNL $5.19
- TLSA $1.20
- Analyst Decision
- PSNL Strong Buy
- TLSA
- Analyst Count
- PSNL 4
- TLSA 0
- Target Price
- PSNL $6.81
- TLSA N/A
- AVG Volume (30 Days)
- PSNL 439.4K
- TLSA 145.8K
- Earning Date
- PSNL 11-06-2024
- TLSA 05-10-2024
- Dividend Yield
- PSNL N/A
- TLSA N/A
- EPS Growth
- PSNL N/A
- TLSA N/A
- EPS
- PSNL N/A
- TLSA N/A
- Revenue
- PSNL $80,027,000.00
- TLSA N/A
- Revenue This Year
- PSNL $10.85
- TLSA N/A
- Revenue Next Year
- PSNL $8.77
- TLSA N/A
- P/E Ratio
- PSNL N/A
- TLSA N/A
- Revenue Growth
- PSNL 19.20
- TLSA N/A
- 52 Week Low
- PSNL $0.89
- TLSA $0.41
- 52 Week High
- PSNL $7.20
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- PSNL 56.29
- TLSA 65.44
- Support Level
- PSNL $4.54
- TLSA $0.83
- Resistance Level
- PSNL $5.35
- TLSA $0.92
- Average True Range (ATR)
- PSNL 0.30
- TLSA 0.09
- MACD
- PSNL 0.05
- TLSA 0.03
- Stochastic Oscillator
- PSNL 84.71
- TLSA 84.52
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.